Emergent Biosolutions (EBS) Given a $80.00 Price Target at Argus

Share on StockTwits

Argus set a $80.00 target price on Emergent Biosolutions (NYSE:EBS) in a report issued on Friday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the company. Cantor Fitzgerald set a $62.00 price target on Emergent Biosolutions and gave the company a buy rating in a report on Thursday, August 9th. Chardan Capital increased their price target on Emergent Biosolutions from $53.00 to $57.00 and gave the company a buy rating in a report on Friday, August 3rd. Goldman Sachs Group raised Emergent Biosolutions from a neutral rating to a buy rating and increased their price target for the company from $60.00 to $75.00 in a report on Friday, November 2nd. Cowen reaffirmed a hold rating and issued a $49.00 price target on shares of Emergent Biosolutions in a report on Wednesday, August 29th. Finally, Wells Fargo & Co set a $65.00 price target on Emergent Biosolutions and gave the company a hold rating in a report on Wednesday, August 29th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $66.25.

Shares of NYSE:EBS traded down $0.02 during midday trading on Friday, hitting $67.54. The company had a trading volume of 285,122 shares, compared to its average volume of 370,379. Emergent Biosolutions has a twelve month low of $36.38 and a twelve month high of $71.01. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.29 and a current ratio of 5.52. The stock has a market cap of $3.54 billion, a PE ratio of 35.55, a P/E/G ratio of 1.58 and a beta of 1.27.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.07). Emergent Biosolutions had a net margin of 14.19% and a return on equity of 12.89%. The company had revenue of $173.70 million during the quarter, compared to analyst estimates of $185.16 million. During the same period in the prior year, the business posted $0.73 EPS. Emergent Biosolutions’s revenue for the quarter was up 16.3% compared to the same quarter last year. As a group, analysts predict that Emergent Biosolutions will post 2.2 earnings per share for the current fiscal year.

In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 36,318 shares of the firm’s stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $55.98, for a total transaction of $2,033,081.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kathryn C. Zoon sold 4,242 shares of the firm’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $69.74, for a total value of $295,837.08. Following the sale, the director now directly owns 33,972 shares of the company’s stock, valued at approximately $2,369,207.28. The disclosure for this sale can be found here. In the last three months, insiders have sold 199,943 shares of company stock valued at $12,115,228. 16.50% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of EBS. BlackRock Inc. increased its stake in Emergent Biosolutions by 18.2% during the third quarter. BlackRock Inc. now owns 6,350,905 shares of the biopharmaceutical company’s stock worth $418,078,000 after acquiring an additional 978,194 shares during the last quarter. Renaissance Technologies LLC increased its stake in Emergent Biosolutions by 10.6% during the second quarter. Renaissance Technologies LLC now owns 2,066,511 shares of the biopharmaceutical company’s stock worth $104,338,000 after acquiring an additional 198,600 shares during the last quarter. FMR LLC increased its stake in Emergent Biosolutions by 192.7% during the second quarter. FMR LLC now owns 290,507 shares of the biopharmaceutical company’s stock worth $14,668,000 after acquiring an additional 191,248 shares during the last quarter. Rice Hall James & Associates LLC increased its stake in Emergent Biosolutions by 18.1% during the second quarter. Rice Hall James & Associates LLC now owns 1,141,021 shares of the biopharmaceutical company’s stock worth $57,610,000 after acquiring an additional 174,614 shares during the last quarter. Finally, Prudential Financial Inc. increased its stake in Emergent Biosolutions by 86.1% during the third quarter. Prudential Financial Inc. now owns 336,554 shares of the biopharmaceutical company’s stock worth $22,156,000 after acquiring an additional 155,666 shares during the last quarter. 82.76% of the stock is owned by institutional investors.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Read More: Tariff

Analyst Recommendations for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply